ASTRAZENECA PLC (ZEG.DE) Stock Fundamental Analysis
FRA:ZEG - Deutsche Boerse Ag - GB0009895292 - Common Stock - Currency: EUR
ZEG gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 51 industry peers in the Pharmaceuticals industry. ZEG scores excellent on profitability, but there are some minor concerns on its financial health. ZEG has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
ZEG had positive earnings in the past year.
ZEG had a positive operating cash flow in the past year.
Each year in the past 5 years ZEG has been profitable.
Each year in the past 5 years ZEG had a positive operating cash flow.
1.2 Ratios
ZEG has a better Return On Assets (7.31%) than 62.75% of its industry peers.
Looking at the Return On Equity, with a value of 18.94%, ZEG is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
The Return On Invested Capital of ZEG (14.10%) is better than 74.51% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ZEG is below the industry average of 15.19%.
The 3 year average ROIC (11.62%) for ZEG is below the current ROIC(14.10%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.31% | ||
| ROE | 18.94% | ||
| ROIC | 14.1% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
1.3 Margins
The Profit Margin of ZEG (14.14%) is better than 70.59% of its industry peers.
In the last couple of years the Profit Margin of ZEG has grown nicely.
The Operating Margin of ZEG (24.05%) is better than 68.63% of its industry peers.
ZEG's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 82.36%, ZEG belongs to the top of the industry, outperforming 84.31% of the companies in the same industry.
ZEG's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.05% | ||
| PM (TTM) | 14.14% | ||
| GM | 82.36% |
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
ZEG has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for ZEG remains at a similar level compared to 1 year ago.
Compared to 5 years ago, ZEG has more shares outstanding
The debt/assets ratio for ZEG is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 4.99 indicates that ZEG is not in any danger for bankruptcy at the moment.
ZEG has a better Altman-Z score (4.99) than 84.31% of its industry peers.
The Debt to FCF ratio of ZEG is 3.46, which is a good value as it means it would take ZEG, 3.46 years of fcf income to pay off all of its debts.
ZEG's Debt to FCF ratio of 3.46 is fine compared to the rest of the industry. ZEG outperforms 62.75% of its industry peers.
ZEG has a Debt/Equity ratio of 0.71. This is a neutral value indicating ZEG is somewhat dependend on debt financing.
ZEG has a Debt to Equity ratio of 0.71. This is comparable to the rest of the industry: ZEG outperforms 45.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.71 | ||
| Debt/FCF | 3.46 | ||
| Altman-Z | 4.99 |
ROIC/WACC1.59
WACC8.87%
2.3 Liquidity
A Current Ratio of 0.90 indicates that ZEG may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.90, ZEG is doing worse than 78.43% of the companies in the same industry.
A Quick Ratio of 0.70 indicates that ZEG may have some problems paying its short term obligations.
The Quick ratio of ZEG (0.70) is worse than 80.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.9 | ||
| Quick Ratio | 0.7 |
3. Growth
3.1 Past
ZEG shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by 0.00%.
The Earnings Per Share has been growing by 18.59% on average over the past years. This is quite good.
The Revenue has grown by 15.48% in the past year. This is quite good.
Measured over the past years, ZEG shows a quite strong growth in Revenue. The Revenue has been growing by 17.27% on average per year.
EPS 1Y (TTM)0%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%-39.81%
Revenue 1Y (TTM)15.48%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%7.17%
3.2 Future
Based on estimates for the next years, ZEG will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.41% on average per year.
Based on estimates for the next years, ZEG will show a small growth in Revenue. The Revenue will grow by 6.41% on average per year.
EPS Next Y12.48%
EPS Next 2Y12.94%
EPS Next 3Y11.87%
EPS Next 5Y11.41%
Revenue Next Year8.37%
Revenue Next 2Y7.23%
Revenue Next 3Y6.74%
Revenue Next 5Y6.41%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
ZEG is valuated rather expensively with a Price/Earnings ratio of 19.10.
Compared to the rest of the industry, the Price/Earnings ratio of ZEG is on the same level as its industry peers.
ZEG is valuated rather cheaply when we compare the Price/Earnings ratio to 26.03, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 13.49, ZEG is valued correctly.
Based on the Price/Forward Earnings ratio, ZEG is valued a bit cheaper than 64.71% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ZEG to the average of the S&P500 Index (21.94), we can say ZEG is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.1 | ||
| Fwd PE | 13.49 |
4.2 Price Multiples
ZEG's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. ZEG is more expensive than 62.75% of the companies in the same industry.
ZEG's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 47.92 | ||
| EV/EBITDA | 23.2 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ZEG has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)1.53
PEG (5Y)1.03
EPS Next 2Y12.94%
EPS Next 3Y11.87%
5. Dividend
5.1 Amount
ZEG has a Yearly Dividend Yield of 2.42%.
ZEG's Dividend Yield is a higher than the industry average which is at 3.09.
ZEG's Dividend Yield is comparable with the S&P500 average which is at 2.36.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.42% |
5.2 History
The dividend of ZEG has a limited annual growth rate of 1.40%.
Dividend Growth(5Y)1.4%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
ZEG pays out 63.60% of its income as dividend. This is not a sustainable payout ratio.
The dividend of ZEG is growing, but earnings are growing more, so the dividend growth is sustainable.
DP63.6%
EPS Next 2Y12.94%
EPS Next 3Y11.87%
FRA:ZEG (5/21/2025, 7:00:00 PM)
124.75
+0.6 (+0.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners47.67%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap386.77B
Analysts82.29
Price Target163.45 (31.02%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.42% |
Yearly Dividend2.67
Dividend Growth(5Y)1.4%
DP63.6%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-23.08%
Min EPS beat(2)-45.53%
Max EPS beat(2)-0.63%
EPS beat(4)1
Avg EPS beat(4)-11.86%
Min EPS beat(4)-45.53%
Max EPS beat(4)0.64%
EPS beat(8)4
Avg EPS beat(8)-4.61%
EPS beat(12)8
Avg EPS beat(12)-0.89%
EPS beat(16)10
Avg EPS beat(16)-0.99%
Revenue beat(2)1
Avg Revenue beat(2)-0.63%
Min Revenue beat(2)-3.96%
Max Revenue beat(2)2.7%
Revenue beat(4)2
Avg Revenue beat(4)-0.21%
Min Revenue beat(4)-3.96%
Max Revenue beat(4)2.7%
Revenue beat(8)4
Avg Revenue beat(8)-0.19%
Revenue beat(12)4
Avg Revenue beat(12)-0.55%
Revenue beat(16)8
Avg Revenue beat(16)0.72%
PT rev (1m)-3.79%
PT rev (3m)1.82%
EPS NQ rev (1m)0.97%
EPS NQ rev (3m)0.4%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.11%
Revenue NQ rev (1m)0.29%
Revenue NQ rev (3m)1.63%
Revenue NY rev (1m)0.84%
Revenue NY rev (3m)1.43%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.1 | ||
| Fwd PE | 13.49 | ||
| P/S | 7.96 | ||
| P/FCF | 47.92 | ||
| P/OCF | 33.46 | ||
| P/B | 10.67 | ||
| P/tB | N/A | ||
| EV/EBITDA | 23.2 |
EPS(TTM)6.53
EY5.23%
EPS(NY)9.25
Fwd EY7.41%
FCF(TTM)2.6
FCFY2.09%
OCF(TTM)3.73
OCFY2.99%
SpS15.66
BVpS11.69
TBVpS-5.03
PEG (NY)1.53
PEG (5Y)1.03
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.31% | ||
| ROE | 18.94% | ||
| ROCE | 17.15% | ||
| ROIC | 14.1% | ||
| ROICexc | 15.14% | ||
| ROICexgc | 76.66% | ||
| OM | 24.05% | ||
| PM (TTM) | 14.14% | ||
| GM | 82.36% | ||
| FCFM | 16.62% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexcg growth 3Y43.28%
ROICexcg growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score9
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.71 | ||
| Debt/FCF | 3.46 | ||
| Debt/EBITDA | 1.47 | ||
| Cap/Depr | 58.81% | ||
| Cap/Sales | 7.18% | ||
| Interest Coverage | 9.49 | ||
| Cash Conversion | 65.63% | ||
| Profit Quality | 117.58% | ||
| Current Ratio | 0.9 | ||
| Quick Ratio | 0.7 | ||
| Altman-Z | 4.99 |
F-Score9
WACC8.87%
ROIC/WACC1.59
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%-39.81%
EPS Next Y12.48%
EPS Next 2Y12.94%
EPS Next 3Y11.87%
EPS Next 5Y11.41%
Revenue 1Y (TTM)15.48%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%7.17%
Revenue Next Year8.37%
Revenue Next 2Y7.23%
Revenue Next 3Y6.74%
Revenue Next 5Y6.41%
EBIT growth 1Y42.22%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year30.69%
EBIT Next 3Y16.62%
EBIT Next 5Y13.31%
FCF growth 1Y51.52%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y34.8%
OCF growth 3Y25.76%
OCF growth 5Y31.92%